DLOCAL
26.10.2021 13:02:06 CEST | Business Wire | Press release
dLocal, a technology-first payments platform that enables global enterprise merchants to connect with billions of consumers in emerging markets, introduced today its latest developments for risk management.
The first product in the stack is Smart Defense , an advanced, custom-built solution that fights fraud based on enhanced data and machine learning models. The program enhances its prediction capability by inspecting a high volume of transactions, not only by blocking suspicious payments but also by approving more genuine purchases. “The more attacks it stops, the smarter it gets,” says Nicolas Aliberti, VP of Fraud Prevention at dLocal. “SmartDefense quickly goes through a massive number of data points such as shopper information, shipping address, item purchased, industry, and device ID, among others, to assess risk and define scoring rules for future transactions.”
Merchants can subscribe to Smart Defense as a standalone feature even when processing their payments through a different PSP. “No other payment facilitator has such a large database of online transactions in emerging countries, where fraud is a critical challenge. Even with another provider, it is a wise option to let dLocal handle your risk management in those markets,” adds Aliberti.
Adjacent to Smart Defense, dLocal presents Defense Manager , a user interface that offers merchants the flexibility to change a predefined set of rules. “Choose the tolerance according to your risk appetite. Decide, for example, which transactions should apply 3D Secure and when to be less conservative in a user-friendly dashboard,” continues Aliberti. This tool puts your fraud team in charge of decision-making and is ideal for companies that already have industry-specific fraud intel and dedicated teams.
Finally, with Chargeback Guarantee , merchants delegate all fraud management responsibilities and costs to dLocal. For a transparent fee based on the volume of approved transactions, online companies without a dedicated fraud management team can leave it to dLocal to configure specific rules and cover all chargeback costs. “As with all our products, we want to make fighting fraud a simple process, even with complex matters such as chargebacks and disputes. Chargeback Guarantee will keep conversion rates high and eliminate the risk of penalties from card schemes. All the merchant needs to worry about is growing their business,” concludes Aliberti.
dLocal’s fraud prevention technology, powered by artificial intelligence, with machine learning algorithms such as XGBoost and deep neural networks checks in real-time and under 100 milliseconds for potentially fraudulent transactions. Each merchant and industry have tailor-made machine learning models that are retrained almost on a daily basis with petabytes of information on millions of transactions from emerging markets. That enables merchants to grow their business, stop fraud and create more revenue from legitimate transactions. dLocal’s exclusive reach and experience make these the most sophisticated fraud prevention systems for emerging markets.
About dLocal
dLocal powers local payments in emerging markets connecting global enterprise merchants with billions of emerging market consumers across APAC, the Middle East, Latin America, and Africa. Through the “One dLocal” concept (one API, one platform, and one contract), global companies can accept payments, send pay-outs, and settle funds globally without the need to manage separate pay-in and pay-out processors, set up numerous local entities, and integrate multiple acquirers and payment methods in each market. Learn more at https://dlocal.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005248/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
